TSC22D1 Human shRNA Plasmid Kit (Locus ID 8848)
CAT#: TR300799
TSC22D1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
Cited in 1 publication. |
Product images
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | TSC22D1 Human shRNA Plasmid Kit (Locus ID 8848) |
Locus ID | 8848 |
UniProt ID | Q15714 |
Synonyms | Ptg-2; TGFB1I4; TSC22 |
Vector | pRS |
Format | Retroviral plasmids |
Kit Components | TSC22D1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 8848). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free. |
RefSeq | NM_001243797, NM_001243798, NM_001243799, NM_006022, NM_183422, NM_006022.1, NM_006022.2, NM_006022.3, NM_183422.1, NM_183422.2, NM_183422.3, NM_001243799.1, NM_001243797.1, NM_001243798.1, BC000456, BC009528, BC016867, BC069207, BC105277, BC136475, BC136482, BC146664, BC146679, NM_183422.4, NM_006022.4 |
Summary | This gene encodes a member of the TSC22 domain family of leucine zipper transcription factors. The encoded protein is stimulated by transforming growth factor beta, and regulates the transcription of multiple genes including C-type natriuretic peptide. The encoded protein may play a critical role in tumor suppression through the induction of cancer cell apoptosis, and a single nucleotide polymorphism in the promoter of this gene has been associated with diabetic nephropathy. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Aug 2011] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Transforming Growth Factor-ß–Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition
,Cynthia C.T. Sprenger, Kathleen Haugk, Shihua Sun, Ilsa Coleman, Peter S. Nelson, Robert L. Vessella, Dale L. Ludwig, Jennifer D. Wu, and Stephen R. Plymate,
Clin. Cancer Res., Dec 2009; 15: 7634 - 7641
[TSC22D1]
|
Documents
Product Manuals |
FAQs |
SDS |
其它TSC22D1产品